Valuation: Clene Inc.

Market Cap 54.44M 48.6M 44.6M 40.57M 76.07M 5.15B 77.58M 533M 215M 2.72B 204M 200M 8.59B P/E 2026 *
-1.4x
P/E 2027 * -2.12x
Enterprise Value 49.84M 44.5M 40.83M 37.14M 69.64M 4.72B 71.03M 488M 197M 2.49B 187M 183M 7.87B EV / Sales 2026 *
200x
EV / Sales 2027 * 2.42x
Free-Float
83.46%
Yield 2026 *
-
Yield 2027 * -
1 day-5.74%
1 week-6.96%
Current month-5.74%
1 month-10.20%
3 months-28.02%
6 months-41.21%
Current year-38.50%
1 week 3.6
Extreme 3.605
4.05
1 month 3.02
Extreme 3.0152
4.11
Current year 3.02
Extreme 3.0152
8.67
1 year 3.02
Extreme 3.0152
13.5
3 years 2.28
Extreme 2.2801
13.5
5 years 2.28
Extreme 2.2801
122.4
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 2013-03-31
Chief Tech/Sci/R&D Officer 67 2012-12-31
Director of Finance/CFO 57 2022-01-31
Director TitleAgeSince
Chairman 65 2015-10-31
Director/Board Member 53 2019-08-31
Director/Board Member 49 2020-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/16/26 Free

Chief Executive Officer

15,244 0.1186%
9/16/26 Free

Chairman

434,451 3.3813%
9/16/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-5.74%-6.96%-71.12%-52.22% 54.44M
-2.37%-4.19%+39.49%+63.21% 63.77B
-2.87%+0.23%+11.11%+68.89% 56.37B
+0.62%+2.60%+16.96%+103.45% 54.62B
-3.33%-7.49%+19.39%+43.57% 44.06B
-2.45%-4.33%+16.36%+99.27% 42.11B
-1.64%+0.63%+219.80%+824.67% 41B
-5.47%+39.86%+101.20%+80.57% 34.92B
+0.21%-1.23%+14.81%+47.35% 32.82B
-2.90%+17.05%-42.35%+337.41% 24.7B
Average -2.59%+6.82%+32.56%+161.62% 39.44B
Weighted average by Cap. -2.16%+5.64%+44.61%+167.79%

Financials

2026 *2027 *
Net sales 249K 223K 204K 186K 348K 23.61M 355K 2.44M 984K 12.46M 936K 916K 39.36M 23.27M 20.77M 19.06M 17.34M 32.51M 2.2B 33.16M 228M 91.77M 1.16B 87.32M 85.46M 3.67B
Net income -34.49M -30.79M -28.26M -25.7M -48.19M -3.27B -49.15M -337M -136M -1.72B -129M -127M -5.44B -31M -27.68M -25.4M -23.1M -43.31M -2.93B -44.18M -303M -122M -1.55B -116M -114M -4.89B
Net Debt -4.6M -4.11M -3.77M -3.43M -6.43M -435M -6.56M -45.01M -18.14M -230M -17.26M -16.9M -726M 1.8M 1.61M 1.47M 1.34M 2.52M 170M 2.57M 17.61M 7.1M 89.94M 6.76M 6.61M 284M
Projected Income Statement - Annual - Clene Inc.
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
-
Date Price Change Volume
26-11-02 $3.610 -5.74% 54,013
26-10-30 $3.830 -1.79% 47,273
26-10-29 $3.900 -3.23% 34,254
26-10-28 $4.030 +1.51% 44,069
26-10-27 $3.970 +3.39% 31,305
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Clene Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.610USD
Average target price
32.20USD
Spread / Average Target
+791.97%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Clene Inc.
  1. Stock Market
  2. Stocks
  3. CLNN Stock